Lee’s Pharmaceutical

Explore the latest insights on Lee’s Pharmaceutical and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Lee’s Pharmaceutical’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Explore the latest insights on Lee's Pharmaceutical and its impact on China's pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Lee's Pharmaceutical's developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

BioPartners X Signs RMB 227 Million Technology Transfer Deal with CAMS for CD132 Autoimmune Antibody
CompanyDeals

BioPartners X Signs RMB 227 Million Technology Transfer Deal with CAMS for CD132 Autoimmune Antibody

BioPartners X announced that it has entered into a technology transfer agreement with the Hospital of Dermatology, Chinese Academy of Medical Sciences (CAMS) for an innovative CD132‑targeting monoclonal antibody, with…

Zhejiang Garden Biopharmaceutical and Guangzhou National Laboratory Form Joint Venture to Develop 25‑Hydroxycholesterol – A Prodrug‑Class Broad‑Spectrum Antiviral Program

Zhejiang Garden Biopharmaceutical and Guangzhou National Laboratory Form Joint Venture to Develop 25‑Hydroxycholesterol – A Prodrug‑Class Broad‑Spectrum Antiviral Program

Adalvo and Jiangsu Sinopep‑Allsino Forge Strategic Partnership – Combining Peptide and Oligonucleotide Manufacturing Expertise with Commercial Reach Across 160+ Markets

Adalvo and Jiangsu Sinopep‑Allsino Forge Strategic Partnership – Combining Peptide and Oligonucleotide Manufacturing Expertise with Commercial Reach Across 160+ Markets

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Zhaoke Ophthalmology's TAB014 Achieves Positive Phase III Results for wAMD
CompanyDrug

Zhaoke Ophthalmology’s TAB014 Achieves Positive Phase III Results for wAMD

Lee's Pharmaceutical Receives NMPA Approval for Generic Glaucoma Treatments
CompanyDrug

Lee’s Pharmaceutical Receives NMPA Approval for Generic Glaucoma Treatments

Windtree Therapeutics Secures Hong Kong Patent for Istaroxime Heart Failure Treatment
CompanyDrug

Windtree Therapeutics Secures Hong Kong Patent for Istaroxime Heart Failure Treatment

Lee’s Pharmaceutical’s Subsidiary Reports Positive Results from Phase III Myopia Treatment Study
CompanyDrug

Lee’s Pharmaceutical’s Subsidiary Reports Positive Results from Phase III Myopia Treatment Study

CompanyDrug

Lee’s Pharmaceutical’s Zhaoke Ophthalmology Receives NMPA Approval for Generic Lumigan

CompanyDrug

Lee’s Pharma Subsidiary Receives Green Light for Phase III Dry Eye Study and Completes Myopia Trial

CompanyDrug

Lee’s Pharmaceutical Commences Phase I Clinical Trial for AI-Discovered HCC Drug AU409

CompanyDeals

Zhaoke Ophthalmology Partners with China’s Eye Valley to Establish Ophthalmic Research Institute

Show More